

Michal Heger, Rowan F. van Golen, Mans Broekgaarden, Martin C. Michel

The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer

Pharmacological Reviews

Table S3 - Skin

Excel file available upon request to Michal Heger

NOTE: cell lines that are listed as being contaminated (see http://www.hpacultures.org.uk/media/EDA/AB/Cross_Contaminations_v6_7.pdf) are indicated in red bold italic font.

	IC ₅₀ or LC ₅₀ [µM]	Incubation time [h]	Cell line	Origin	Reference
SQUAMOUS CELLS	2.2	72	A431	Human squamous cell carcinoma	14
	15<IC50<20	72	A431	Human squamous cell carcinoma	19
	±4	96	A431	Human squamous cell carcinoma	23
	5<IC50<10	120	A431	Human squamous cell carcinoma	37
MELANOCYTES	±20	36	4046GT	Mouse melanoma	132
	±40	48	B16	Mouse melanoma	56
	15<IC50<20	48	B16	Mouse melanoma	92
	8.2±1.0	48	B16/F10	Mouse melanoma	64
	18	48	B16-R	Mouse melanoma	168
	20<IC50<40	48	WM-15	Human melanoma	56
	10<IC50<20	48	A375	Human melanoma	109
	±20	48	Hs294T	Human melanoma	109
	20<IC50<30	48	1106 Mel	Human melanoma	109
	20<IC50<30	48	FO1	Human melanoma	109
	4.28±0.35	48	UACC-62	Human melanoma	174
	30<IC50<60	48	MMRU	Human melanoma	177
	30<IC50<60	48	RPEP	Human melanoma	177
	30<IC50<60	48	PMWK	Human melanoma	177
	30<IC50<60	48	Sk-mel-2	Human melanoma	177
	30<IC50<60	48	Sk-mel-5	Human melanoma	177
	30<IC50<60	48	Sk-mel-28	Human melanoma	177
	10<IC50<25	72	A375	Human melanoma	77
	15<IC50<50	96	A375	Human melanoma	169
	±7.5	96	G361	Human melanoma	23
	±50	96	MeWo	Human melanoma	169